This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Proliferative diabetic retinopathy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This type of retinopathy is the most severe complication of diabetic eye disease and usually follows pre-proliferative retinopathy.

  • Proliferative diabetic retinopathy (PDR) is the angiogenic response of the retina to extensive capillary closure.
  • New vessels grow at the interface of perfused and nonperfused retina and are described as new vessels on the disc (NVD) or new vessels elsewhere (NVE) (1).

It is seen most commonly in young patients who have been treated by insulin for at least 10 years.

The Wisconsin Epidemiologic Study of Diabetic Retinopathy showed proliferative retinopathy varied from 1.2% to 67% in persons with diabetes for less than ten years and 35 or more years, respectively.

Uncontrolled proliferation results in advanced diabetic eye disease with secondary glaucoma and retinal detachment (1).

Reference:

  1. The Royal College of Ophthalmologists (RCOphth) 2012. Diabetic retinopathy guidelines
  2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984 Apr;102(4):520-6.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.